Predictive Biomarkers of Bacillus Calmette-Guérin Immunotherapy Response in Bladder Cancer: Where Are We Now? by Luís Lima, Mário Dinis-Ribeiro, Adhemar Longatto-Filho, Lúcio Santos

Get full text

Development and interpretation of a pathomics-driven ensemble model for predicting the response to immunotherapy in gastric cancer by Jing Wang, Zhe Li, Wei Wang, Md Tauhidul Islam, Xiaoyan Wang, Zhen Han, Zihan Li, Guoxin Li, Yuming Jiang, Taojun Zhang, Wenjun Xiong, Zepang Sun, Lequan Yu, Zhicheng Zhang, Xianqi Yang, Shengtian Sang, Alyssa A Guo

“…Journal for ImmunoTherapy of Cancer…”
Get full text

Circulating MMP-12 as Potential Biomarker in Evaluating Disease Severity and Efficacy of Sublingual Immunotherapy in Allergic Rhinitis by Yandan Zhou, Min Xu, Wei Gong, Xiaoming Kang, Renzhong Guo, Jie Wen, Dinggang Zhou, Manjing Wang, Dazhi Shi, Qiancheng Jing

“…All AR patients were assigned to receive sublingual immunotherapy (SLIT), and the efficacy was evaluated, and serum samples were collected at 1 year and 3 years after treatment. …”
Get full text

Prognostic Impact of Adjuvant Immunotherapy in Patients With Resectable NSCLC After Neoadjuvant Chemoimmunotherapy: A Brief Report by Yichen Dong, MD, Long Xu, MD, Jialiang Wen, MD, Haojie Si, MD, Juemin Yu, MD, Tao Chen, MD, Huikang Xie, MD, Xinjian Li, MD, Minglei Yang, MD, Junqiang Fan, MD, Junqi Wu, MD, Yunlang She, MD, Deping Zhao, MD, Chang Chen, MD, PhD

Subjects: Get full text

A new paradigm for cancer immunotherapy: Orchestrating type 1 and type 2 immunity for curative response by Bing Feng, Li Tang

Subjects: “…cancer immunotherapy…”
Get full text

Correction: The performance status gap in immunotherapy for frail patients with advanced non-small cell lung cancer by Julie Tsu-Yu Wu, June Corrigan, Chloe Su, Clark Dumontier, Jennifer La, Aparajita Khan, Shipra Arya, Alex H. S. Harris, Leah Backhus, Millie Das, Nhan V. Do, Mary T. Brophy, Summer S. Han, Michael Kelley, Nathanael R. Fillmore

“…Cancer Immunology, Immunotherapy…”
Get full text

Evaluation of treatment strategies for patients with stage IIIA non-small cell lung cancer in the immunotherapy era by Amy Alabaster, Jeffrey B. Velotta, Haley I. Tupper, Mark S. Walker, Yanina Natanzon

Subjects: Get full text

Comprehensive analysis of publications concerning combinations of immunotherapy and targeted therapies for hepatocellular carcinoma: a bibliometric study by Biling Gan, Lei Wu, Shunan Zhou, Zhihong Chen, Fan Wu, Lianqun Xu, Zhenrong Chen, Honghui Ma, Peijia He, Dan Fang, Ning Shi

Subjects: Get full text

TUBA1B as a novel prognostic biomarker correlated with immunosuppressive tumor microenvironment and immunotherapy response by Juntao Qi, Juntao Qi, Mingming Zhou, Na Yang, Huiyun Ma, Min He, Gujie Wu, Chang Ge, Liuyin Jin, Lin Cheng, Wei Liao, Hefei Ren, Caiyun Lei

“…Despite its fundamental roles, TUBA1B’s impact on tumor prognosis and the tumor immune microenvironment across cancer types remains inadequately understood.Methods To elucidate TUBA1B’s role in cancer prognosis and immune response, we conducted a comprehensive analysis, integrating data from established databases such as The Cancer Genome Atlas, Genotype Tissue Expression, Cancer Cell Lineage Encyclopedia, Human Protein Atlas, Kaplan-Meier Plotter, cBioPortal, TIMER, and ImmuCellAI, along with a large-scale clinical study and immunotherapy cohort. We also conducted in vitro functional assays to assess TUBA1B’s functional role in tumor cells, allowing for a detailed examination of its relationship with cancer prognosis and immune modulation.Results: Our findings indicate that TUBA1B expression is dysregulated across multiple cancers, correlating strongly with poor survival outcomes and advanced pathological stages. …”
Get full text

Physical parameters and biological factors affect the abscopal effect of combining radiotherapy with immunotherapy: an update on preclinical works by Wangcai Ren, Jialing Wen, Gang Guo, Gang Guo, Wenchao Gu, Shenke Zhang, Shenke Zhang, Chang Liu, Chang Liu, Kensuke Osada, Takashi Shimokawa, Qiaojuan Wang, Qiaojuan Wang, Yue Wang, Yue Wang, Xuanzhang Tu, Chen Li, Li Sui, Liqiu Ma, Liqiu Ma, Liqiu Ma

Get full text

A Full GMP Process to Select and Amplify Epitope-Specific T Lymphocytes for Adoptive Immunotherapy of Metastatic Melanoma by N. Labarriere, A. Fortun, A. Bellec, A. Khammari, B. Dreno, S. Saïagh, F. Lang

Get full text

Adeno-associated virus mediated artificial circular RNA for triggering cancer immunotherapy to treat prostate cancer by Chujin Ye, Chujin Ye, Zhiye Liu, Zhiye Liu, Qifan Xie, Qifan Xie, Yanlin Tang, Yanlin Tang, Jiayi Zeng, Jiayi Zeng, Ziwei Feng, Ziwei Feng, Jiumin Liu, Jiumin Liu, Haibiao Xie, Haibiao Xie

Subjects: Get full text

Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations by Sophia Kreft, Tommaso Bosetti, Rebecca Lee, Paul Lorigan

“…Immunotherapy has dramatically changed the outcome for patients with advanced melanoma, with significant improvements in overall survival and potential cure for some. …”
Get full text

Exploring Clec9a in dendritic cell-based tumor immunotherapy for molecular insights and therapeutic potentials by Zubair Hussain, Yueteng Zhang, Lu Qiu, Shanshan Gou, Kangdong Liu

“…Abstract The pivotal role of type 1 conventional dendritic cells (cDC1s) in the field of dendritic cell (DC)-based tumor immunotherapies has been gaining increasing recognition due to their superior antigen cross-presentation abilities and essential role in modulating immune responses. …”
Get full text

Bibliometric insight into neoadjuvant immunotherapy in non-small cell lung cancer: trends, collaborations, and future avenues by Pengliang Xu, Huanming Yu, Hupo Bian, Dan Jia, Wenhui Li, Hongfeng Dong, Xiuhua Peng

Subjects: Get full text

Research on therapeutic clinical trials including immunotherapy in triple-negative breast cancer: a bibliometric analysis by Qi Xu, Xiaoyu Feng, Siyuan Qin, Yu Hong, Rui Cui, Jia Liang, Zhuya Xiao, Yuan Li

Subjects: Get full text

Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy by R. Ortenberg, S. Sapoznik, D. Zippel, R. Shapira-Frommer, O. Itzhaki, A. Kubi, D. Zikich, M. J. Besser, J. Schachter, G. Markel

“…Moreover, we demonstrate that serum CEACAM1 is elevated over time in progressive melanoma patients who fail to respond to immunotherapy as opposed to responders and stable disease patients, thus proving a correlation between sCEACAM1, response to treatment, and clinical deterioration.…”
Get full text

Construction and Characterization of Adenovirus Vectors Encoding Aspartate-β-Hydroxylase to Preliminary Application in Immunotherapy of Hepatocellular Carcinoma by Yujiao Zhou, Feifei Liu, Chengmin Li, Guo Shi, Xiaolei Xu, Xue Luo, Yuanling Zhang, Jingjie Fu, Aizhong Zeng, Limin Chen

“…Dendritic cells (DCs) harboring tumor-associated antigen are supposed to be a potential immunotherapy for hepatocellular carcinoma (HCC). Aspartate-β-hydroxylase (AAH), an overexpressed tumor-associated cell surface protein, is considered as a promising biomarker and therapeutic target for HCC. …”
Get full text

CDC20‐Mediated Selective Autophagy Degradation of PBRM1 Affects Immunotherapy for Renal Cell Carcinoma by Yizeng Fan, Weichao Dan, Taotao Que, Yi Wei, Bo Liu, Zixi Wang, Yulin Zhang, Yuzhao Wang, Tianjie Liu, Yanxin Zhuang, Mengxing Li, Chendong Guo, Jin Zeng, Bohan Ma, Lei Li

Subjects: Get full text

Pre-immunotherapy alters stereotactic ablative radiotherapy-induced systemic T cell responses in early-stage NSCLC by Chao Liu, Yanjuan Chen, Xiaohui Li, Zhijie Bai, Meilin Jiang, Dongsheng Sheng, Wenxue Zou, Rui Huang, Qingyu Huang, Fuhao Wang, Jingyang Zhu, Huiru Sun, Bing Liu, Zongcheng Li, Bing Sun

Subjects: Get full text